Impact of performance status and age on osimertinib efficacy in patients with EGFR-mutant T790M-positive non-small-cell lung cancer

Activating epidermal growth factor receptor (EGFR) mutations are reported in 30–40% of Asiatic patients and in 10–15% of unselected Caucasian patients with advanced non-small cell lung cancer (NSCLC) (1).